
CLAIMS

What is claimed is:


1. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein a therapeutically effective amount of (i) Compound A or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, and (ii) daratumumab is to be administered to a patient in need of such treatment or management.

2. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein a therapeutically effective amount of (i) Compound A or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, (ii) daratumumab and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered to a patient in need of such treatment or management.

3. The use according to claim 1 or 2, wherein the cancer is multiple myeloma.

4. The use according to claim 3, wherein the multiple myeloma is smoldering myeloma, indolent myeloma, active multiple myeloma, extramedullary plasmacytoma, solitary plasmacytoma of the bone, light chain myeloma, or non-secretory myeloma.

5. The use according to claim 3, wherein the multiple myeloma is relapsed or refractory.

6. The use according to claim 3, wherein the multiple myeloma is drug-resistant.

7. The use according to 3, wherein the multiple myeloma is newly diagnosed.

8. Use of a compound in the manufacture of a medicament for treating or managing multiple myeloma, wherein the compound is Compound A, or an enantiomer or mixture of

enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein:
a therapeutically effective amount of (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab is to be administered to a patient, wherein the patient is identified as having multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal clathrate or polymorph thereof and (b) daratumumab.

9. Use of a compound in the manufacture of a medicament for treating or managing multiple myeloma, wherein the compound is Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein a therapeutically effective amount of (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered to a patient, wherein the patient is identified as having multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

10. The use according to claim 8 or 9, wherein the multiple myeloma is relapsed or refractory.

11. The use according to claim 8 or 9, wherein the multiple myeloma is drug-resistant.

12. The use according to claim 8 or 9, wherein the multiple myeloma is newly diagnosed.

13. The use according to any one of claims 2-12, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate,

hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 0.5 to about 100 mg per day, and (ii) daratumumab is administered in an amount of from about 16 to about 200 mg/kg per day.

14. The use according to any one of claims 2-12, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 0.5 to about 100 mg per day, (ii) daratumumab is administered in an amount of from about 16 to about 200 mg/kg per day and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 20 to about 200 mg.

15. The use according to claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 0.5 to about 5 mg per day, and (ii) daratumumab is to be administered in an amount of from about 16 to about 25 mg/kg per day.

16. The use according to claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of about 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 or 100 mg per day, and (ii) daratumumab is to be administered in an amount of about 16, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg/kg per day.

17. The use according to claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered orally and (ii) daratumumab is to be administered intravenously.

18. The use according to claim 13, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in a capsule or tablet and (ii) daratumumab is to be administered by injection or infusion.

19. The use according to claim 18, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in 10 mg or 25 mg of a capsule and (ii) daratumumab is to be administered as intravenous infusion of diluted 20 mg/ml single dose vial.

20. The use according to claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of from about 0.5 to about 5 mg per day, (ii) daratumumab is to be administered in an amount of from about 16 to about 25 mg/kg per day and (iii) dexamethasone is to be administered in an amount of from about 20 to about 50 mg per day.

21. The use according to claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of about 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 or 100 mg per day, (ii) daratumumab is to be administered in an amount of about 16, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg/kg per day and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, is to be administered in an amount of about 20, 25, 30, 35, 40, 45, 50, 75, 100, 150 or 200 mg per day.

22. The use according to claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered orally, (ii) daratumumab is to be administered intravenously and (iii) dexamethasone is to be administered orally or by injection.

23. The use according to claim 14, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is to be administered in a capsule or tablet, (ii) daratumumab is to be administered by injection or infusion and (iii) dexamethasone is to be administered in a tablet.


24. The use according to claim 23, wherein (i) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal,

clathrate, or polymorph thereof is to be administered in 10 mg or 25 mg of a capsule, (ii) daratumumab is to be administered as intravenous infusion of diluted 20 mg/ml single dose vial and (iii) dexamethasone is to be administered as 0.5 mg or 0.75 mg of a tablet.

25. The use according to claim any one of claims 2-24, wherein the multiple myeloma is relapsed, refractory or resistant to conventional therapy.

26. The use according to claim any one of claims 2-25, wherein the compounds are to be administered in a 28-day cycle.

27. The use according to claim any one of claims 2-26, wherein the compound is Compound A-S



Compound A-S

or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.